CTL019

Phase 3Biologic

Novartis

CTL019 is one of 106 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaUnknown

B-Cell Acute Lymphoblastic LeukemiaRecruiting

LymphomaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPreclinical

Unknown

B-Cell Acute Lymphoblastic LeukemiaPhase 3

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CTL019

Novartis

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT04094311

Q4 2027

Phase 2Active, not recruiting

Efficacy and Safety

NCT03876769

Clinical

Trials by Indication[1]

Efficacy and Safety4 trials

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02228096·75 enrolled

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Withdrawn·—·Phase 2·NCT02167360

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02435849·80 enrolled

Show 1 more trial

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT03876769·121 enrolled

DLBCL1 trial

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available· Novartis logo

Novartis··NCT03601442

Acute Lymphoblastic Leukemia1 trial

Phase III B in Acute Lymphoblastic Leukemia

Completed· Novartis logo

Novartis·Phase 3·NCT03123939·69 enrolled

Lymphoma1 trial

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT04161118·3 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication

Recruiting· Novartis logo

Novartis·Phase 3·NCT04094311·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for CTL019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTL019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTL019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Novartis

CTL019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Efficacy and Safety4 trials

DLBCL1 trial

Acute Lymphoblastic Leukemia1 trial

Lymphoma1 trial

B-cell acute lymphoblastic leukemia1 trial

References

Drug Info

Quick Facts

Related News